Abstract
Carvedilol, a third-generation and nonselective β-adrenoceptor antagonist, is a licensed drug for treating patients suffering from heart failure in clinics. It has been shown that Carvedilol protects cells against mitochondrial dysfunction. However, it's unknown whether Carvedilol affects mitochondrial biogenesis. In this study, we found that treatment with Carvedilol in HUVECs resulted in a significant increase of PGC-1α, NRF1, and TFAM. Notably, Carvedilol significantly increased mtDNA contents and the two mitochondrial proteins, cytochrome C and COX IV. In addition, MitoTracker Red staining results indicated that treatment with Carvedilol increased mitochondria mass. Mechanistically, we found that the effect of Carvedilol on the expression of PGC-1α is mediated by the PKA-CREB pathway. Importantly, our results revealed that stimulation of mitochondrial biogenesis by carvedilol resulted in functional gain of the mitochondria by showing increased oxygen consumption and mitochondrial respiratory rate. The increased expression of PGC-1α and mitochondrial biogenesis induced by Carvedilol might suggest a new mechanism of the therapeutic effects of Carvedilol in heart failure.
References
May 23, 1996·The New England Journal of Medicine·M PackerN H Shusterman
Jul 21, 1999·Cell·Z WuB M Spiegelman
Sep 28, 2000·Biochemical and Biophysical Research Communications·P J OliveiraA J Moreno
Feb 7, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·J WanagatJ M Aiken
May 29, 2002·Biochimica Et Biophysica Acta·Richard C Scarpulla
Dec 9, 2003·European Journal of Pharmacology·Pedro MonteiroLuís A Providência
Apr 28, 2005·Current Vascular Pharmacology·Paulo J OliveiraAntonio J Moreno
Feb 28, 2006·Circulation Journal : Official Journal of the Japanese Circulation Society·Ryosuke KametaniMasunori Matsuzaki
Apr 28, 2007·Circulation Research·Sean M Davidson, Michael R Duchen
Aug 18, 2009·Naunyn-Schmiedeberg's Archives of Pharmacology·Anil KumarAtish Prakash
May 12, 2011·Journal of Cardiovascular Pharmacology·Yaser CheemaKarl T Weber
Oct 14, 2011·Stem Cell Reviews and Reports·Richard D W KellyJustin C St John
Dec 22, 2011·Future Cardiology·Giuseppe LimongelliPerry M Elliott
Sep 4, 2012·Trends in Cardiovascular Medicine·Christian Riehle, E Dale Abel
Nov 20, 2012·Annual Review of Physiology·Peter Dromparis, Evangelos D Michelakis
Jan 31, 2013·Toxicology and Applied Pharmacology·Hany H Arab, Maha M El-Sawalhi
Nov 15, 2013·BMC Cardiovascular Disorders·Ge Li-ShaLi Yue-Chun
Citations
Feb 16, 2017·Physiological Reports·Adil BashirW Todd Cade
Sep 25, 2018·Journal of Cellular and Molecular Medicine·Heike WankaJörg Peters
Feb 12, 2019·PloS One·Li HuChunmei Xia
Apr 13, 2020·Journal of Cellular and Molecular Medicine·Lucia-Doina Popov
May 28, 2020·European Heart Journal·Milton Packer
Apr 29, 2020·Aging·Yanping LiuXiyuan Lu
Feb 26, 2020·Archives of Physiology and Biochemistry·Dan ChenLongguang Li
May 7, 2020·Frontiers in Pharmacology·Qian ZhangYong Wang
Nov 7, 2019·Frontiers in Pharmacology·Xin GuanTao Pang
May 7, 2020·Signal Transduction and Targeted Therapy·Yang LiuJinliang Xing
Mar 11, 2020·Frontiers in Pharmacology·Zhenyu ZhuXin Qi
Sep 1, 2017·Scientific Reports·Xue ZhangGuanhua Du
Nov 23, 2017·Obesity·Rodney A VelliquetteKelly Glynn
Mar 14, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Daniella Medina-RuizCésar Ibarra-Alvarado
Apr 2, 2016·International Neurourology Journal·Jubert MarquezJin Han
Mar 28, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Lu YanMin Wei
Aug 14, 2020·Journal of the American Heart Association·Milton Packer
Sep 16, 2020·British Journal of Pharmacology·Berna GüvenArzu Onay-Beşikci
Jul 10, 2020·Cancer Discovery·Nesrine ArouaJean-Emmanuel Sarry
Feb 13, 2021·Oxidative Medicine and Cellular Longevity·Rodrigo CarrascoPaaladinesh Thavendiranathan
Jul 3, 2021·Cells·Mariona Guitart-MampelMaria E Solesio